| Dokumentenart: | Artikel | ||||
|---|---|---|---|---|---|
| Titel eines Journals oder einer Zeitschrift: | Molecular Cancer Therapeutics | ||||
| Verlag: | AMER ASSOC CANCER RESEARCH | ||||
| Ort der Veröffentlichung: | PHILADELPHIA | ||||
| Band: | 6 | ||||
| Nummer des Zeitschriftenheftes oder des Kapitels: | 3 | ||||
| Seitenbereich: | S. 1123-1132 | ||||
| Datum: | 2007 | ||||
| Institutionen: | Medizin > Lehrstuhl für Chirurgie Medizin > Lehrstuhl für Pathologie | ||||
| Identifikationsnummer: |
| ||||
| Stichwörter / Keywords: | HYPOXIA-INDUCIBLE FACTOR-1-ALPHA; RECEPTOR TYROSINE KINASE; SHOCK-PROTEIN 90; HSP90 INHIBITORS; BINDING PROTEIN; PHASE-I; ANGIOGENESIS; EXPRESSION; GELDANAMYCIN; OVEREXPRESSION; | ||||
| Dewey-Dezimal-Klassifikation: | 600 Technik, Medizin, angewandte Wissenschaften > 610 Medizin | ||||
| Status: | Veröffentlicht | ||||
| Begutachtet: | Ja, diese Version wurde begutachtet | ||||
| An der Universität Regensburg entstanden: | Ja | ||||
| Dokumenten-ID: | 69358 |
Web of ScienceZusammenfassung
Oncogenic signaling through activation of epidermal growth factor receptor (EGFR), HER-2, and hypoxia inducible-factor-1 alpha (HIF-1 alpha) has been implicated in gastric cancer growth and angiogenesis through upregulation of vascular endothelial growth factor (VEGF). Recently, heat shock protein 90 (Hsp90) has been identified as a critical regulator of oncogenic protein stability, including ...
Zusammenfassung
Oncogenic signaling through activation of epidermal growth factor receptor (EGFR), HER-2, and hypoxia inducible-factor-1 alpha (HIF-1 alpha) has been implicated in gastric cancer growth and angiogenesis through upregulation of vascular endothelial growth factor (VEGF). Recently, heat shock protein 90 (Hsp90) has been identified as a critical regulator of oncogenic protein stability, including EGFR, HER-2, and HIF-1 alpha. We hypothesized that inhibition of Hsp90 impairs EGF- and hypoxiamediated angiogenic signaling in gastric cancer cells and consequently inhibits angiogenesis and tumor growth. In vitro, the geldanamycin derivate 17-allylamino-17-demethoxygeldanamycin (17-AAG) led to marked reduction in constitutive and inducible activation of extracellular signal-regulated kinase 1/2, Akt, and signal transducer and activator of transcription 3 and decreased nuclear HIF-1 alpha protein. In addition, EGFR and HER-2 were down-regulated after Hsp90 inhibition. With respect to regulation of angiogenic molecules, 17-AAG significantly reduced EGF-mediated VEGF secretion. Phosphorylation of focal adhesion kinase and paxillin were both abrogated by 17-AAG, which resulted in significant impairment of cancer cell motility. Interestingly, cytotoxic effects of 17-AAG in vitro were higher on cancer cells and gastric fibroblasts than on pericytes. In vivo, the water-soluble compound 17-dimethylaminoethylamino-17-demethoxygeldanamycin (17-DMAG; 25 mg/kg, thrice per week) significantly reduced s.c. xenografted tumor growth. By immunohistochemistry, 17-DMAG significantly reduced vessel area and numbers of proliferating tumor cells in sections. Furthermore, similar significant growth-inhibitory effects of 17-DMAG were achieved when administered as low-dose therapy (5 mg/kg, thrice per week). In conclusion, blocking Hsp90 disrupts multiple proangiogenic signaling pathways in gastric cancer cells and inhibits xenografted tumor growth in vivo. Hence, gastric cancer harbors attractive molecular targets for therapy with Hsp90 inhibitors, which could lead to improved efficacy of antineoplastic therapy regimens.
Metadaten zuletzt geändert: 19 Dez 2024 13:58
Altmetric